Steve Chadban

Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

Peter W. Nickerson, Georg A. Böhmig, Steve Chadban, Deepali Kumar et autres

Abstract Background Chronic active antibody-mediated rejection (AMR) is a major cause of graft loss with no approved drugs for its treatment. Currently, off-label regimens are used, reflecting the high unmet need for effective therapies based on well-controlled trials. Clazakizumab is a high-affinity, …

ca, at, au, us, nl (code pays fourni par la source)

Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study

Olivier Aubert, Gillian Divard, Julio Pascual, Federico Oppenheimer et autres

OBJECTIVES: Development of pharmaceutical agents in transplantation is currently limited by long waits for hard endpoints. We applied a validated integrative risk-prognostication system integrative Box (iBox) as a surrogate endpoint to the TRANSFORM Study, a large randomised controlled trial, to project individual …

fr, es, de, it, br, au, us, jp, ch (code pays fourni par la source)

Kidney transplant recipient perspectives on telehealth during the COVID‐19 pandemic

Brooke M. Huuskes, Nicole Jane Scholes-Robertson, Chandana Guha, Amanda Baumgart et autres

The COVID-19 pandemic has challenged the delivery of health services. Telehealth allows delivery of care without in-person contacts and minimizes the risk of vial transmission. We aimed to describe the perspectives of kidney transplant recipients on the benefits, challenges, and risks of …

au (code pays fourni par la source)

Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance

Stephen Boyle, Joshua W.D. Tobin, Jacinta Perram, Nada Hamad et autres

Introduction Post-transplant lymphoproliferative disorders (PTLD) are aggressive lymphomas which occur in solid organ transplant recipients and cause significant mortality. In the era of positron emission tomography (PET) staging and rituximab (R), there is limited real-world data on treatment outcomes and the incidence …

au, us (code pays fourni par la source)

TARGETING INFLAMMATORY MONOCYTES BY IMMUNE-MODIFYING NANOPARTICLES PREVENTS ACUTE KIDNEY ALLOGRAFT REJECTION

Christina Lai, Steve Chadban, Julian Singer, Yik Wen Loh et autres

Aim: We previously reported the capacity of immune-modifying nanoparticles (IMPs) to bind to circulating inflammatory monocytes/macrophages (MΦ) via the specific scavenger receptor MARCO, thereby causing MΦ removal in the spleen with subsequent protection in models of infection, autoimmunity and ischemia-reperfusion injury (IRI). …

au (code pays fourni par la source)

Ethical Issues in the COVID Era: Doing the Right Thing Depends on Location, Resources, and Disease Burden

Peter G. Stock, Anji Elizabeth Wall, James Morgan Gardner, Beatriz Domínguez‐Gil et autres

INTRODUCTION The transplant community is well-versed in ethical issues surrounding the allocation of scarce resources, but the COVID-19 pandemic has escalated moral dilemmas of transplantation far beyond simply allocation of limited donor organs. Emanuel et al1 were unfortunately prophetic in their recent …

us, es, au, Afrique du Sud, nz (code pays fourni par la source)

Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop

Allison Tong, Braden Manns, Angela Yee‐Moon Wang, Brenda R. Hemmelgarn et autres

There are an estimated 14,000 randomized trials published in chronic kidney disease. The most frequently reported outcomes are biochemical endpoints, rather than clinical and patient-reported outcomes including cardiovascular disease, mortality, and quality of life. While many trials have focused on optimizing kidney …

au, ca, cn, hk, gb, br, be, us, fr (code pays fourni par la source)

Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?

Germaine Wong, Aron Chakera, Jeremy Robert Chapman, Steve Chadban et autres

BACKGROUND: The role of cytomegalovirus (CMV) in cancer development after transplantation remains uncertain. We aimed to determine the association between donor and recipient CMV serological status and the risk of cancer development after kidney transplantation. METHODS: Using data from the Australian and …

au, nz (code pays fourni par la source)

Role of TLRs and DAMPs in allograft inflammation and transplant outcomes

Faouzi Braza, Sophie Brouard, Steve Chadban, Daniel R. Goldstein

pt, fr, au, us (code pays fourni par la source)

List of Contributors

Marcin Adamczak, Talat Alp Ikizler, James Lynch Bailey, Radhakrishna Baliga et autres

pl, us, au, fr, se, sg (code pays fourni par la source)

HMGB1 Preconditioning Protects Against Kidney Ischemia Reperfusion Injury

Huanhuan Wu, Renske Steenstra, Elianne C.S. de Boer, Chengguo Zhao et autres

High-mobility group box1 (HMGB1), a nuclear factor that is released extracellularly as an inflammatory cytokine, is also an endogenous ligand for Toll like receptor 4 (TLR4). We have reported that endogenous HMGB1 mediates kidney ischemia reperfusion injury (IRI) via TLR4 signaling. We …

au (code pays fourni par la source)

Factors that influence the decision to be an organ donor: a systematic review of the qualitative literature

Michelle J. Irving, Allison Tong, Stephen Jan, Alan Cass et autres

BACKGROUND: Transplantation is the treatment of choice for organ failure, but a worldwide shortage of suitable organs exists. We conducted a systematic review of qualitative studies that explored community attitudes towards living and deceased solid organ donation to inform strategies to improve …

au (code pays fourni par la source)